Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Centre Hospitalier Universitaire Vaudois
Multitude Therapeutics Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University of Magdeburg
Chinese PLA General Hospital
National Cancer Institute (NCI)